{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vinorelbine&page=2", "query": { "intervention": "Vinorelbine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vinorelbine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T08:08:43.990Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01565083", "title": "A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 213, "start_date": "2012-04", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-09-29T08:08:43.990Z", "location_count": 17, "location_summary": "Tucson, Arizona • Stanford, California • Denver, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01565083" }, { "nct_id": "NCT00540982", "title": "Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "indocyanine green", "type": "DRUG" }, { "name": "lidocaine", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" }, { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "intracellular fluorescence polarization analysis", "type": "OTHER" }, { "name": "liquid chromatography", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 47, "start_date": "1997-02-20", "completion_date": "2010-05-20", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-09-29T08:08:43.990Z", "location_count": 2, "location_summary": "Duarte, California • Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00540982" }, { "nct_id": "NCT00004096", "title": "Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-09-29T08:08:43.990Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004096" }, { "nct_id": "NCT00477035", "title": "Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "CIK cells", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "bcnu", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sally Arai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 22, "start_date": "2006-05", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-09-29T08:08:43.990Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477035" }, { "nct_id": "NCT04697628", "title": "Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "tisotumab vedotin", "type": "DRUG" }, { "name": "topotecan", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 502, "start_date": "2021-02-22", "completion_date": "2026-01-15", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-09-29T08:08:43.990Z", "location_count": 53, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 28 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697628" }, { "nct_id": "NCT02925000", "title": "Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "TLC178", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiwan Liposome Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2017-06-19", "completion_date": "2020-10-06", "has_results": false, "last_update_posted_date": "2021-07-23", "last_synced_at": "2026-09-29T08:08:43.990Z", "location_count": 2, "location_summary": "Detroit, Michigan • The Bronx, New York", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02925000" }, { "nct_id": "NCT03386721", "title": "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers" ], "interventions": [ { "name": "simlukafusp alfa", "type": "DRUG" }, { "name": "Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2018-02-19", "completion_date": "2021-12-30", "has_results": true, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-09-29T08:08:43.990Z", "location_count": 2, "location_summary": "San Francisco, California • Newnan, Georgia", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386721" }, { "nct_id": "NCT00641160", "title": "Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nonhematologic Malignancies" ], "interventions": [ { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Metronome Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2008-03", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2008-09-26", "last_synced_at": "2026-09-29T08:08:43.990Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00641160" }, { "nct_id": "NCT00026156", "title": "S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2001-11", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-09-29T08:08:43.990Z", "location_count": 96, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026156" }, { "nct_id": "NCT01104259", "title": "Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor-negative Breast Cancer", "HER2-negative Breast Cancer", "Hereditary Breast/Ovarian Cancer - BRCA1", "Hereditary Breast/Ovarian Cancer - BRCA2", "Male Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer", "Triple-negative Breast Cancer" ], "interventions": [ { "name": "veliparib", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-07", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-08-10", "last_synced_at": "2026-09-29T08:08:43.990Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01104259" } ] }